Duvelisib, a novel oral dual inhibitor of PI3K-d,g, is clinically active in advanced hematologic malignancies
Ian W. Flinn, Susan O’Brien, Brad Kahl, Manish Patel, Yasuhiro Oki, Francine F. Foss, Pierluigi Porcu, Jeffrey Jones, Jan A. Burger, Nitin Jain, Virginia M. Kelly, Kerstin Allen, Mark Douglas, Jennifer Sweeney, Patrick Kelly, Steven Horwitz
Dive into the research topics of 'Duvelisib, a novel oral dual inhibitor of PI3K-d,g, is clinically active in advanced hematologic malignancies'. Together they form a unique fingerprint.